Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000521

Nevirapine for peak identification

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Nevirapine, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H14N4O
Número de CAS:
129618-40-2
Peso molecular:
266.30
Número MDL:
MFCD00866928
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831002
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

nevirapine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O

InChI

1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

Clave InChI

NQDJXKOVJZTUJA-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Nevirapine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000520

Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard

Y0001499

Nevirapine hemihydrate, European Pharmacopoeia (EP) Reference Standard

1460703

Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard

1460714

Nevirapine hemihydrate, United States Pharmacopeia (USP) Reference Standard

1460725

Nevirapine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1460736

Nevirapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1460747

Nevirapine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1757

Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1760

Nevirapine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1761

Nevirapine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1762

Nevirapine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Laura O Coster et al.
AIDS reviews, 14(2), 132-144 (2012-05-26)
Nevirapine was the first nonnucleoside reverse transcriptase inhibitor that was approved for treatment of HIV infection and quickly became an important component of HAART. As experience with this drug grew, potential toxicities and significant clinical benefits became apparent. With the
Ebrahim Bera et al.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 102(11 Pt 1), 855-859 (2012-11-03)
The package insert for nevirapine (NVP) cautions use in HIV-infected women (including pregnant women) with CD4 counts ≥250 cells/µl. However, recent studies showed that the CD4 count of pregnant women receiving antiretroviral therapy (ART) was not predictive of NVP toxicity.
Patrice Muret et al.
Therapie, 66(3), 187-195 (2011-08-09)
Nevirapine, a HIV non nucleosidic reverse transcriptase inhibitor, displays an inter-individual variability in its pharmacokinetics parameters, related to its hepatic metabolism. Based on literature, is the nevirapine therapeutic drug monitoring relevant? In naïve and pre-treated HIV infected patients, the probability
Nathan Ford et al.
AIDS (London, England), 27(7), 1135-1143 (2013-01-10)
The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women. We conducted a systematic review and meta-analysis of severe adverse events in HIV-positive women who initiated NVP while pregnant. We searched six
Ushma Mehta et al.
The Lancet. Infectious diseases, 7(11), 733-738 (2007-10-27)
The non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are chemically distinct, but both may cause cutaneous hypersensitivity and hepatotoxicity. We reviewed the literature to assess the evidence for cross-reactivity between nevirapine and efavirenz. All papers, abstracts, or presentations, regardless
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico